T helper type 2-polarized invariant natural killer T cells reduce disease severity in acute intra-abdominal sepsis

Clinical and Experimental Immunology

Volumn 178, Issue 2, 2014, Pages 292-309

  Anantha, R V ^a   Mazzuca, D M ^a   Xu, S X ^a   Porcelli, S A ^e   Fraser, D D ^b,c   Martin, C M ^c   Welch, I ^a   Mele, T ^a,c,d   Haeryfar, S M M ^a,d   Mccormick, J K ^a,d  

^a WESTERN UNIVERSITY   (Canada)

^b CHILDREN S HEALTH RESEARCH INSTITUTE   (Canada)

^c LONDON HEALTH SCIENCES CENTRE   (Canada)

^d UNIVERSITY OF WESTERN ONTARIO   (Canada)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Acute intra abdominal sepsis; Glycolipids; Invariant natural killer T cells; Th2 response

Indexed keywords

AUTACOID; CYTOKINE; GLYCOLIPID; TETRACOSANOIC ACID 1-GALACTOPYRANOSYLOXY-3,4-DIHYDROXYDEC-2-YL AMIDE;

ADULT; AGED; ANIMAL; ANTIBODY SPECIFICITY; APOPTOSIS; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; FEMALE; HUMAN; IMMUNOLOGY; LYMPHOCYTE COUNT; MALE; METABOLISM; MIDDLE AGED; MORTALITY; MOUSE; NATURAL KILLER T CELL; OUTCOME ASSESSMENT; PATHOLOGY; SEPSIS; SEVERITY OF ILLNESS INDEX; SPLEEN; TH2 CELL;

ADULT; AGED; ANIMALS; APOPTOSIS; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; GLYCOLIPIDS; HUMANS; INFLAMMATION MEDIATORS; LYMPHOCYTE COUNT; MALE; MICE; MIDDLE AGED; NATURAL KILLER T-CELLS; ORGAN SPECIFICITY; PATIENT OUTCOME ASSESSMENT; SEPSIS; SEVERITY OF ILLNESS INDEX; SPLEEN; TH2 CELLS;

EID: 84908164732     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12404     Document Type: Article

References (103)

1. Bone RC, Balk RA, Cerra FB etal. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. 1992. Chest 2009; 136:e28.
2. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-1310.
3. Parrillo JE, Parker MM, Natanson C etal. Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med 1990; 113:227-242.
4. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348:138-150.
5. Dremsizov T, Clermont G, Kellum JA, Kalassian KG, Fine MJ, Angus DC. Severe sepsis in community-acquired pneumonia: when does it happen, and do systemic inflammatory response syndrome criteria help predict course? Chest 2006; 129:968-978.
6. Bozza FA, Salluh JI, Japiassu AM etal. Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis. Crit Care 2007; 11:R49.
7. Bone RC. Sepsis, the sepsis syndrome, multi-organ failure: a plea for comparable definitions. Ann Intern Med 1991; 114:332-333.
8. Pinsky MR, Vincent JL, Deviere J, Alegre M, Kahn RJ, Dupont E. Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest 1993; 103:565-575.
9. Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis 2013; 13:260-268.
10. Miellot-Gafsou A, Biton J, Bourgeois E, Herbelin A, Boissier MC, Bessis N. Early activation of invariant natural killer T cells in a rheumatoid arthritis model and application to disease treatment. Immunology 2010; 130:296-306.
11. Van Kaer L. alpha-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles. Nat Rev Immunol 2005; 5:31-42.
12. Walker KM, Rytelewski M, Mazzuca DM etal. Preventing and curing citrulline-induced autoimmune arthritis in a humanized mouse model using a Th2-polarizing iNKT cell agonist. Immunol Cell Biol 2012; 90:630-639.
13. Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol 2007; 25:297-336.
14. Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L. NKT cells: what's in a name? Nat Rev Immunol 2004; 4:231-237.
15. Hu CK, Venet F, Heffernan DS etal. The role of hepatic invariant NKT cells in systemic/local inflammation and mortality during polymicrobial septic shock. J Immunol 2009; 182:2467-2475.
16. Kinjo Y, Illarionov P, Vela JL etal. Invariant natural killer T cells recognize glycolipids from pathogenic Gram-positive bacteria. Nat Immunol 2011; 12:966-974.
17. Barral P, Sanchez-Nino MD, van Rooijen N, Cerundolo V, Batista FD. The location of splenic NKT cells favours their rapid activation by blood-borne antigen. EMBO J 2012; 31:2378-2390.
18. Kronenberg M. Toward an understanding of NKT cell biology: progress and paradoxes. Annu Rev Immunol 2005; 23:877-900.
19. Dieli F, Sireci G, Russo D etal. Resistance of natural killer T cell-deficient mice to systemic Shwartzman reaction. J Exp Med 2000; 192:1645-1652.
20. Brigl M, Bry L, Kent SC, Gumperz JE, Brenner MB. Mechanism of CD1d-restricted natural killer T cell activation during microbial infection. Nat Immunol 2003; 4:1230-1237.
21. Skold M, Behar SM. Role of CD1d-restricted NKT cells in microbial immunity. Infect Immun 2003; 71:5447-5455.
22. Leung B, Harris HW. NKT cells: the culprits of sepsis? J Surg Res 2011; 167:87-95.
23. Haeryfar SM, Lan Z, Leon-Ponte M etal. Prolongation of cardiac allograft survival by rapamycin and the invariant natural killer T cell glycolipid agonist OCH. Transplantation 2008; 86:460-468.
24. Parekh VV, Wilson MT, Olivares-Villagomez D etal. Glycolipid antigen induces long-term natural killer T cell anergy in mice. J Clin Invest 2005; 115:2572-2583.
25. Hashimoto D, Asakura S, Miyake S etal. Stimulation of host NKT cells by synthetic glycolipid regulates acute graft-versus-host disease by inducing Th2 polarization of donor T cells. J Immunol 2005; 174:551-556.
26. Oki S, Chiba A, Yamamura T, Miyake S. The clinical implication and molecular mechanism of preferential IL-4 production by modified glycolipid-stimulated NKT cells. J Clin Invest 2004; 113:1631-1640.
27. Shrum B, Anantha RV, Xu SX etal. A robust scoring system to evaluate sepsis severity in an animal model. BMC Res Notes 2014; 7:233.
28. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2013; 310:2191-2194.
29. Levy MM, Fink MP, Marshall JC etal. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med 2003; 31:1250-1256.
30. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13:818-829.
31. Knaus WA, Zimmerman JE, Wagner DP, Draper EA, Lawrence DE. APACHE-acute physiology and chronic health evaluation: a physiologically based classification system. Crit Care Med 1981; 9:591-597.
32. Hayworth JL, Mazzuca DM, Maleki Vareki S, Welch I, McCormick JK, Haeryfar SM. CD1d-independent activation of mouse and human iNKT cells by bacterial superantigens. Immunol Cell Biol 2012; 90:699-709.
33. Cui J, Shin T, Kawano T etal. Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science 1997; 278:1623-1626.
34. Goff RD, Gao Y, Mattner J etal. Effects of lipid chain lengths in alpha-galactosylceramides on cytokine release by natural killer T cells. J Am Chem Soc 2004; 126:13602-13603.
35. Ly D, Tohn R, Rubin B etal. An alpha-galactosylceramide C20:2 N-acyl variant enhances anti-inflammatory and regulatory T cell-independent responses that prevent type 1 diabetes. Clin Exp Immunol 2010; 160:185-198.
36. Tohn R, Blumenfeld H, Haeryfar SM etal. Stimulation of a shorter duration in the state of anergy by an invariant natural killer T cell agonist enhances its efficiency of protection from type 1 diabetes. Clin Exp Immunol 2011; 164:26-41.
37. Bustin SA, Benes V, Garson JA etal. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 2009; 55:611-622.
38. Pavlidis P, Noble WS. Matrix2png: a utility for visualizing matrix data. Bioinformatics 2003; 19:295-296.
39. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol 2007; 35:495-516.
40. Gentile LF, Nacionales DC, Lopez MC etal. Host responses to sepsis vary in different low-lethality murine models. PLOS ONE 2014; 9:e94404.
41. Gauzit R, Pean Y, Barth X, Mistretta F, Lalaude O. Epidemiology, management, and prognosis of secondary non-postoperative peritonitis: a French prospective observational multicenter study. Surg Infect (Larchmt) 2009; 10:119-127.
42. Stetson DB, Mohrs M, Reinhardt RL etal. Constitutive cytokine mRNAs mark natural killer (NK) and NK T cells poised for rapid effector function. J Exp Med 2003; 198:1069-1076.
43. Yu KO, Im JS, Molano A etal. Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of alpha-galactosylceramides. Proc Natl Acad Sci USA 2005; 102:3383-3388.
44. Shah S, Lowery E, Braun RK etal. Cellular basis of tissue regeneration by omentum. PLOS ONE 2012; 7:e38368.
45. Wilson MT, Johansson C, Olivares-Villagomez D etal. The response of natural killer T cells to glycolipid antigens is characterized by surface receptor down-modulation and expansion. Proc Natl Acad Sci USA 2003; 100:10913-10918.
46. Harada M, Seino K, Wakao H etal. Down-regulation of the invariant Valpha14 antigen receptor in NKT cells upon activation. Int Immunol 2004; 16:241-247.
47. Matsuda JL, Gapin L, Baron JL etal. Mouse V alpha 14i natural killer T cells are resistant to cytokine polarization in vivo. Proc Natl Acad Sci USA 2003; 100:8395-8400.
48. Gapin L, Matsuda JL, Surh CD, Kronenberg M. NKT cells derive from double-positive thymocytes that are positively selected by CD1d. Nat Immunol 2001; 2:971-978.
49. Mizuno M, Masumura M, Tomi C etal. Synthetic glycolipid OCH prevents insulitis and diabetes in NOD mice. J Autoimmun 2004; 23:293-300.
50. Chiba A, Oki S, Miyamoto K, Hashimoto H, Yamamura T, Miyake S. Suppression of collagen-induced arthritis by natural killer T cell activation with OCH, a sphingosine-truncated analog of alpha-galactosylceramide. Arthritis Rheum 2004; 50:305-313.
51. Hotchkiss RS, Swanson PE, Freeman BD etal. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med 1999; 27:1230-1251.
52. Alberti C, Brun-Buisson C, Chevret S etal. Systemic inflammatory response and progression to severe sepsis in critically ill infected patients. Am J Respir Crit Care Med 2005; 171:461-468.
53. Riedemann NC, Guo RF, Ward PA. Novel strategies for the treatment of sepsis. Nat Med 2003; 9:517-524.
54. Ulloa L, Tracey KJ. The 'cytokine profile': a code for sepsis. Trends Mol Med 2005; 11:56-63.
55. Miyamoto K, Miyake S, Yamamura T. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 2001; 413:531-534.
56. Kawano T, Cui J, Koezuka Y etal. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 1997; 278:1626-1629.
57. Esperatti M, Ferrer M, Giunta V etal. Validation of predictors of adverse outcomes in hospital-acquired pneumonia in the ICU. Crit Care Med 2013; 41:2151-2161.
58. Amato MB, Barbas CS, Medeiros DM etal. Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome. N Engl J Med 1998; 338:347-354.
59. Dellinger RP, Carlet JM, Masur H etal. Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004; 32:858-873.
60. Wheeler AP, Bernard GR. Treating patients with severe sepsis. N Engl J Med 1999; 340:207-214.
61. Stanic AK, Shashidharamurthy R, Bezbradica JS etal. Another view of T cell antigen recognition: cooperative engagement of glycolipid antigens by Va14Ja18 natural T(iNKT) cell receptor [corrected]. J Immunol 2003; 171:4539-4551.
62. Van Dissel JT, Van Langevelde P, Westendorp RGJ, Kwappenberg K, Frölich M. Anti-inflammatory cytokine profile and mortality in febrile patients. Lancet 1998; 351:950-953.
63. Ertel W, Kremer JP, Kenney J etal. Downregulation of proinflammatory cytokine release in whole blood from septic patients. Blood 1995; 85:1341-1347.
64. Munoz C, Carlet J, Fitting C, Misset B, Bleriot JP, Cavaillon JM. Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest 1991; 88:1747-1754.
65. Rigato O, Salomao R. Impaired production of interferon-gamma and tumor necrosis factor-alpha but not of interleukin 10 in whole blood of patients with sepsis. Shock 2003; 19:113-116.
66. Boomer JS, To K, Chang KC etal. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 2011; 306:2594-2605.
67. Otto G, Sossdorf M, Claus R etal. The late phase of sepsis is characterized by an increased microbiological burden and death rate. Crit Care 2011; 15:R183.
68. Kollef KE, Schramm GE, Wills AR, Reichley RM, Micek ST, Kollef MH. Predictors of 30-day mortality and hospital costs in patients with ventilator-associated pneumonia attributed to potentially antibiotic-resistant gram-negative bacteria. Chest 2008; 134:281-287.
69. Limaye AP, Kirby KA, Rubenfeld GD etal. Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA 2008; 300:413-422.
70. Luyt CE, Combes A, Deback C etal. Herpes simplex virus lung infection in patients undergoing prolonged mechanical ventilation. Am J Respir Crit Care Med 2007; 175:935-942.
71. Hotchkiss RS, Nicholson DW. Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol 2006; 6:813-822.
72. Hotchkiss RS, Tinsley KW, Swanson PE etal. Prevention of lymphocyte cell death in sepsis improves survival in mice. Proc Natl Acad Sci USA 1999; 96:14541-14546.
73. Hotchkiss RS, Tinsley KW, Swanson PE etal. Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J Immunol 2001; 166:6952-6963.
74. Taniguchi M, Seino K, Nakayama T. The NKT cell system: bridging innate and acquired immunity. Nat Immunol 2003; 4:1164-1165.
75. Smyth MJ, Thia KY, Street SE etal. Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med 2000; 191:661-668.
76. Morecki S, Panigrahi S, Pizov G etal. Effect of KRN7000 on induced graft-vs-host disease. Exp Hematol 2004; 32:630-637.
77. Nakano Y, Onozuka K, Terada Y, Shinomiya H, Nakano M. Protective effect of recombinant tumor necrosis factor-alpha in murine salmonellosis. J Immunol 1990; 144:1935-1941.
78. Doherty GM, Lange JR, Langstein HN, Alexander HR, Buresh CM, Norton JA. Evidence for IFN-gamma as a mediator of the lethality of endotoxin and tumor necrosis factor-alpha. J Immunol 1992; 149:1666-1670.
79. Hayworth JL, Kasper KJ, Leon-Ponte M etal. Attenuation of massive cytokine response to the staphylococcal enterotoxin B superantigen by the innate immunomodulatory protein lactoferrin. Clin Exp Immunol 2009; 157:60-70.
80. Matsukawa A, Hogaboam CM, Lukacs NW etal. Expression and contribution of endogenous IL-13 in an experimental model of sepsis. J Immunol 2000; 164:2738-2744.
81. Wynn TA. IL-13 effector functions. Annu Rev Immunol 2003; 21:425-456.
82. Muchamuel T, Menon S, Pisacane P, Howard MC, Cockayne DA. IL-13 protects mice from lipopolysaccharide-induced lethal endotoxemia: correlation with down-modulation of TNF-alpha, IFN-gamma, and IL-12 production. J Immunol 1997; 158:2898-2903.
83. Yu KO, Porcelli SA. The diverse functions of CD1d-restricted NKT cells and their potential for immunotherapy. Immunol Lett 2005; 100:42-55.
84. Cannaday JE. Some uses of undetached omentum in surgery. Am J Surg 1948; 76:502-505.
85. Van Vugt E, Van Rijthoven EA, Kamperdijk EW, Beelen RH. Omental milky spots in the local immune response in the peritoneal cavity of rats. Anat Rec 1996; 244:235-245.
86. Lynch L, O'Shea D, Winter DC, Geoghegan J, Doherty DG, O'Farrelly C. Invariant NKT cells and CD1d(+) cells amass in human omentum and are depleted in patients with cancer and obesity. Eur J Immunol 2009; 39:1893-1901.
87. Carlow DA, Gold MR, Ziltener HJ. Lymphocytes in the peritoneum home to the omentum and are activated by resident dendritic cells. J Immunol 2009; 183:1155-1165.
88. Lin H, Nieda M, Hutton JF, Rozenkov V, Nicol AJ. Comparative gene expression analysis of NKT cell subpopulations. J Leukoc Biol 2006; 80:164-173.
89. Lin H, Nieda M, Nicol AJ. Differential proliferative response of NKT cell subpopulations to in vitro stimulation in presence of different cytokines. Eur J Immunol 2004; 34:2664-2671.
90. Lee HH, Meyer EH, Goya S etal. Apoptotic cells activate NKT cells through T cell Ig-like mucin-like-1 resulting in airway hyperreactivity. J Immunol 2010; 185:5225-5235.
91. Wermeling F, Lind SM, Jordo ED, Cardell SL, Karlsson MC. Invariant NKT cells limit activation of autoreactive CD1d-positive B cells. J Exp Med 2010; 207:943-952.
92. Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol 2013; 13:862-874.
93. Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, Henson PM. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest 1998; 101:890-898.
94. Heffernan DS, Monaghan SF, Chung CS, Cioffi WG, Gravenstein S, Ayala A. A divergent response of innate regulatory T-cells to sepsis in humans: circulating invariant natural killer T-cells are preserved. Hum Immunol 2013; 75:277-282.
95. Cohen J, Opal S, Calandra T. Sepsis studies need new direction. Lancet Infect Dis 2012; 12:503-505.
96. Vincent JL, Sun Q, Dubois MJ. Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clin Infect Dis 2002; 34:1084-1093.
97. Meisel C, Schefold JC, Pschowski R etal. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med 2009; 180:640-648.
98. Hall M, Knatz N, Vetterly C etal. Immunoparalysis and nosocomial infection in children with multiple organ dysfunction syndrome. Intens Care Med 2011; 37:525-532.
99. Morre M, Beq S. Interleukin-7 and immune reconstitution in cancer patients: a new paradigm for dramatically increasing overall survival. Target Oncol 2012; 7:55-68.
100. Mackall CL, Fry TJ, Gress RE. Harnessing the biology of IL-7 for therapeutic application. Nat Rev Immunol 2011; 11:330-342.
101. Rosenberg SA, Sportes C, Ahmadzadeh M etal. IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J Immunother 2006; 29:313-319.
102. Pellegrini M, Calzascia T, Toe JG etal. IL-7 engages multiple mechanisms to overcome chronic viral infection and limit organ pathology. Cell 2011; 144:601-613.
103. Kasten KR, Prakash PS, Unsinger J etal. Interleukin-7 (IL-7) treatment accelerates neutrophil recruitment through gamma delta T-cell IL-17 production in a murine model of sepsis. Infect Immun 2010; 78:4714-4722.